Prograf is named as an intervention in 7 current clinical trials in our Canada, Sweden and Norway registers. 3 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Boston Children's Hospital (1). The most-studied condition is Dyskeratosis Congenita.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Dyskeratosis Congenita | 1 |
| Hoyeraal Hreidarsson Syndrome | 1 |
| Revesz Syndrome | 1 |
| Aplastic Anemia | 1 |
| Sickle Cell Disease | 1 |
| Liver Transplantation | 1 |
| Immunosuppression | 1 |
| Neurotoxicity | 1 |
| Tremor | 1 |
| Organ Transplant Failure or Rejection | 1 |
| Brain Death | 1 |
| Ischemic Reperfusion Injury | 1 |
| Kidney Transplant | 1 |
| Liver Transplant; Complications | 1 |
| Renal Insufficiency | 1 |
| Immunosuppressant Adverse Reaction | 1 |
| Metabolic Syndrome | 1 |
| Liver Transplant Rejection | 1 |
| Immune System Suppression | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Canada | 6 | 3 |
| Clinical trials in Sweden | 1 | 0 |
| Clinical trials in Norway | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
7 current trials in our Canada, Sweden and Norway registers name Prograf as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 7 trials are recruiting: 3 with sites in Canada. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Boston Children's Hospital (1), Emory University (1), University of British Columbia (1) and Université de Sherbrooke (1), among 7 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Prograf works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Prograf works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Prograf (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.